Companies are raising money in Asian-Pacific equity markets at the fastest pace since the global financial crisis.
Just 15 days into the new year, initial public offerings (IPOs) have reached US$5.9 billion, the most since 2007 for the period, data compiled by Bloomberg showed.
Chinese companies are leading the fundraising, accounting for 97 percent of the proceeds raised, the data showed.
The Chinese dominance is no surprise with Beijing-Shanghai High Speed Railway Co (京滬高鐵) clinching the biggest deal in Asia this year, raising US$4.3 billion in China.
Alibaba Group Holding Ltd’s (阿里巴巴) second listing in Hong Kong last year has set the stage for other Chinese companies that are considering doing the same, which bodes well for Asia-Pacific IPO volume this year.
The e-commerce giant’s Hong Kong shares have surged about 25 percent since its listing in November last year.
Trip.com Group Ltd (攜程) and Netease Inc (網易), both of which are trading on the NASDAQ, are said to be in preliminary discussions with the exchange for a potential second listing in Hong Kong
A secondary listing is seen as a hedge by Chinese companies listed in the US, as the administration of US President Donald Trump is looking at various ways to curb their access to US funding.
There are 196 Chinese companies listed on major US exchanges with a combined market value US$1.2 trillion, Bloomberg’s data showed.
Among those firms, BeiGene Ltd (百濟神州) and Alibaba are the only two with a second listing in Hong Kong.
In other IPO news, UK drugmaker GlaxoSmithKline PLC has not made plans to pursue an IPO of the consumer-health company it set up with Pfizer Inc last year, a top executive said on Wednesday, rowing back remarks made by Pfizer’s chief executive on Tuesday
The comments could expose a lack of communication between the two partners.
Pfizer chief executive Albert Bourla on Tuesday said that he expected Glaxo to pursue an IPO in three to four years.
“This is the time that we will be able to exit from this partnership, and I’m sure that this business will have a fantastic IPO,” Bourla said at the JPMorgan Healthcare Conference in San Francisco.
However, Glaxo chief strategy officer David Redfern said in an interview at the meeting on Wednesday that an IPO is not the only option.
Glaxo said at the time of the deal that it would separate and list the company within three to five years.
“Actually, we haven’t decided anything,” Redfern said. “When we announced the deal, we said we expect it to separate within three years, but actually up to five years. And it’s entirely our decision.”
Glaxo, the majority owner, and Pfizer, which has about a third of the business, are looking to focus on drug development.
With an approval rating of just two percent, Peruvian President Dina Boluarte might be the world’s most unpopular leader, according to pollsters. Protests greeted her rise to power 29 months ago, and have marked her entire term — joined by assorted scandals, investigations, controversies and a surge in gang violence. The 63-year-old is the target of a dozen probes, including for her alleged failure to declare gifts of luxury jewels and watches, a scandal inevitably dubbed “Rolexgate.” She is also under the microscope for a two-week undeclared absence for nose surgery — which she insists was medical, not cosmetic — and is
GROWING CONCERN: Some senior Trump administration officials opposed the UAE expansion over fears that another TSMC project could jeopardize its US investment Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) is evaluating building an advanced production facility in the United Arab Emirates (UAE) and has discussed the possibility with officials in US President Donald Trump’s administration, people familiar with the matter said, in a potentially major bet on the Middle East that would only come to fruition with Washington’s approval. The company has had multiple meetings in the past few months with US Special Envoy to the Middle East Steve Witkoff and officials from MGX, an influential investment vehicle overseen by the UAE president’s brother, the people said. The conversations are a continuation of talks that
CAUTIOUS RECOVERY: While the manufacturing sector returned to growth amid the US-China trade truce, firms remain wary as uncertainty clouds the outlook, the CIER said The local manufacturing sector returned to expansion last month, as the official purchasing managers’ index (PMI) rose 2.1 points to 51.0, driven by a temporary easing in US-China trade tensions, the Chung-Hua Institution for Economic Research (CIER, 中華經濟研究院) said yesterday. The PMI gauges the health of the manufacturing industry, with readings above 50 indicating expansion and those below 50 signaling contraction. “Firms are not as pessimistic as they were in April, but they remain far from optimistic,” CIER president Lien Hsien-ming (連賢明) said at a news conference. The full impact of US tariff decisions is unlikely to become clear until later this month
Nintendo Co hopes to match the runaway success of the Switch when its leveled-up new console hits shelves on Thursday, with strong early sales expected despite the gadget’s high price. Featuring a bigger screen and more processing power, the Switch 2 is an upgrade to its predecessor, which has sold 152 million units since launching in 2017 — making it the third-best-selling video game console of all time. However, despite buzz among fans and robust demand for pre-orders, headwinds for Nintendo include uncertainty over US trade tariffs and whether enough people are willing to shell out. The Switch 2 “is priced relatively high”
RSS